Market Overview

UPDATE: Jefferies Lowers PT on Johnson & Johnson Following Global Pharma Review

Related JNJ
Stocks Hitting 52-Week Highs
New Active ETF for All Risk Environments
U.S., U.K. ISIS Response Differ Widely (Fox Business)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Johnson & Johnson (NYSE: JNJ), but lowered the price target from $97.00 to $91.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Johnson & Johnson closed on Thursday at $83.68.

Latest Ratings for JNJ

DateFirmActionFromTo
Aug 2014JefferiesMaintainsHold
Jul 2014CitigroupMaintainsBuy
Jul 2014Deutsche BankMaintainsHold

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (JNJ)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters